









Markets
/
Stocks
/
nasdaq-mynz
/

Mainz Biomed NV

MYNZ

1.390USD

-0.075-5.12%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

5.69MMarket Cap

LossP/E TTM



Mainz Biomed NV

1.390

-0.075-5.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mainz Biomed NV

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mainz Biomed NV's Score

Industry at a Glance

Industry Ranking

59 / 78

Overall Ranking

374 / 4616

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+855.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mainz Biomed NV Highlights

StrengthsRisks

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 68.72% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 893.99K.

Overvalued

The company’s latest PE is -0.06, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 386.03K shares, increasing 27.28% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.83, which is lower than the Healthcare Providers & Services industry's average of 7.24. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.83

Change



Financials

5.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.78

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.47

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.97

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Mainz Biomed NV's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.02, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -0.06, which is -6.11% below the recent high of -0.06 and -3934.24% above the recent low of -2.51.

Score

Industry at a Glance

Previous score

8.02

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/78

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Providers & Services industry's average of 7.56. The average price target for Mainz Biomed NV is 14.00, with a high of 14.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+855.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Mainz Biomed NV

MYNZ

CVS Health Corp

CVS

HCA Healthcare Inc

HCA

Teladoc Health Inc

TDOC

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 1.34, which is lower than the Healthcare Providers & Services industry's average of 7.02. Sideways: Currently, the stock price is trading between the resistance level at 1.62 and the support level at 1.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.66

Change

-0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.021

Sell

RSI(14)

38.671

Neutral

STOCH(KDJ)(9,3,3)

13.272

Sell

ATR(14)

0.113

High Vlolatility

CCI(14)

-137.304

Sell

Williams %R

93.548

Oversold

TRIX(12,20)

-0.242

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.459

Sell

MA10

1.516

Sell

MA20

1.524

Sell

MA50

1.586

Sell

MA100

1.629

Sell

MA200

2.810

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

285.00K

+44.96%

Dauntless Investment Group, LLC

50.00K

Fur Wiederaufbau (Kredianstalt)

23.20K

-25.00%

Baechler (Guido)

20.06K

+6.65%

Hekland (Hans)

17.77K

-0.84%

Journey Advisory Group, LLC

15.00K

LPL Financial LLC

11.73K

Steward Partners Investment Advisory, LLC

10.00K

+900.00%

UBS Financial Services, Inc.

9.81K

+413.24%

Caragol (William J)

7.90K

+48.56%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.97, which is lower than the Healthcare Providers & Services industry's average of 5.44. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.